Results 191 to 200 of about 1,557,457 (269)

Statin Initiation and Mortality After Colorectal Cancer Treatment.

JAMA Netw Open
Woo HT, Shin A.
europepmc   +1 more source

Modeling the Potential Impact of Scaling Up Event-Driven PrEP Among Gay, Bisexual, and Other Men who have Sex with Men. [PDF]

J Acquir Immune Defic Syndr
Chandra C, Maloney KM, Le Guillou A, Hoover KW, Jenness SM.   +4 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Crack initiation and propagation at crack tips of prefabricated flawed sandstone under uniaxial compression. [PDF]

Sci Rep
Jiang C, Zhang X, Wang Y, Hei Q, Ma H, Huai H.   +5 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Regulatory reform and adult methylphenidate dispensing in France: a nationwide interrupted time-series study. [PDF]

BMJ Ment Health
Saint-Dizier C, Therribout N, Carton L, Icick R, Mercier P, Caron C, Bubrovszky M, Hamroun A, Génin M, Lamer A.   +9 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP-4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation. [PDF]

Clin Pharmacol Ther
Ah YM, Nam J, Youn JW, Yu YM, Kang S.
europepmc   +1 more source